Finance professionals in Biotechnology
This biotechnology finance group draws on Intellia Therapeutics, Vir Biotechnology, Legend Biotech, BlueRock Therapeutics and Tessera Therapeutics, among others, and six of the ten currently hold FP&A, controller or accounting titles. They suit biotech teams building a budget around uncertain program timelines, preparing for an IPO or setting up a close process at a young company.
Professionals to explore
Azfar Qureshi
LinkedInExperience: Vice President of Financial Planning Analysis · Vir Biotechnology, Inc.
Azfar Qureshi describes building FP&A functions from scratch and being the first finance hire at three companies, with capital allocation, long-range planning and valuation as focus areas. Azfar has been Vice President of Financial Planning Analysis at Vir Biotechnology, Inc. since 2025, and held Vice President of Finance And Operations and Vice President of Financial Planning Analysis at Element Science, Inc. (2023–2025) and Head of Finance at CellFE Biotech / Tizona Therapeutics (2022–2023).
Is this you? Claim your profile and get paid for calls.
Estee Silk
LinkedInExperience: Corporate Controller · iBio, Inc.
Estee Silk has been Corporate Controller at iBio, Inc. since 2021, a role Estee describes as SVP and Corporate Controller, and was Senior Director, Financial Reporting at Teva Pharmaceuticals (2000–2021), Senior Accountant at Sanofi (1998–2000) and Auditor at KPMG (1995–1998). Two decades of financial reporting at Teva make Estee a fit for financial reporting questions.
Is this you? Claim your profile and get paid for calls.
Geraldine Hegarty
LinkedInExperience: Former Senior Director, Finance and Controller · Ascidian Therapeutics
Geraldine Hegarty, a Chartered Accountant, became Senior Director, Finance and Controller at Ascidian Therapeutics in 2026 after Director, Controller there (2023–2026). Before Ascidian, Geraldine was Associate Director (2022–2023), Managing Consultant (2020–2021) and Senior Consultant (2017–2019) at CrossCountry Consulting and cites Big 4 audit and accounting advisory work, a fit for questions on setting up controllership at a biotech.
Is this you? Claim your profile and get paid for calls.
Jaimy Mauricio
LinkedInExperience: Sr. Director Financial Planning & Analysis · Intellia Therapeutics, Inc.
Jaimy Mauricio has been Sr. Director Financial Planning & Analysis at Intellia Therapeutics, Inc. since 2023, and was Sr. Director Finance, Operations Controller (2022–2023) and Finance Site Controller (2019–2023) at Rubius Therapeutics, Finance Director, Head of Finance for Biologics Operations at Takeda (2018–2019) and Associate Director of Finance, US Operations at Alexion Pharmaceuticals, Inc. (2015–2018). A chemical engineering degree and operations background suit R&D and operations budgeting questions.
Is this you? Claim your profile and get paid for calls.
Jamie Caswell
LinkedInExperience: Senior Director, FP&A · Vir Biotechnology, Inc.
Jamie Caswell was Senior Director, FP&A at Vir Biotechnology, Inc. (2023–2025) and has been Director, US Value and Access at Amgen since 2025, a title also held there in 2021–2023. Other Amgen titles are Director, Operations Finance (2019–2021) and Director, Finance Transformation (2018–2019), and Jamie describes over 25 years at the intersection of finance and biotechnology, a fit for FP&A and US value and access questions.
Is this you? Claim your profile and get paid for calls.
Julie Jones
LinkedInExperience: Former Regional Chief Financial Officer Emerging & Partner Markets (Global Biopharma) · Biogen
Julie Jones was Regional Chief Financial Officer Emerging & Partner Markets (Global Biopharma) at Biogen (2022–2026) and FP&A Director at Alnylam Pharmaceuticals (2026). Other Biogen titles are Finance Director Emerging Markets Expansion Strategy (2021–2022), Director of Global Trade Compliance & Risk Management (2018–2021) and Director, Global PMO Biopharma Manufacturing Expansion (2016–2018), a fit for regional P&L and market expansion questions.
Is this you? Claim your profile and get paid for calls.
Parker Munson
LinkedInExperience: Director of Finance, US EU Head NASDAQ LEGN · Legend Biotech
Parker Munson's Legend Biotech titles are Director of Finance, US EU Head NASDAQ LEGN since 2024, Associate Director of Finance, US EU Head NASDAQ LEGN (2023–2024), Finance Manager, US Site Head NASDAQ LEGN (2021–2023) and Senior Financial Analyst, Cell Therapy Pre IPO (2020–2021). Parker describes FP&A and accounting across manufacturing operations, including launching three international sites, a fit for site budgeting questions.
Is this you? Claim your profile and get paid for calls.
Robert Hill
LinkedInExperience: Senior Director Finance - Controller · Genetix Biotherapeutics
Robert Hill has been Senior Director Finance - Controller at Genetix Biotherapeutics since 2025, after Director - US Controller at Adaptimmune (2023–2025), Senior director of Finance and Commercial Controller at Novan, Inc. (2023), Director of Finance & Assistant Controller at Renovacor (2022–2023) and Associate Director - Accounting and Controls Lead - TBS at Takeda (2019–2022). Robert cites timely closes and SOX compliance.
Is this you? Claim your profile and get paid for calls.
Stephen Garbacz
LinkedInExperience: Former SVP Finance and Corporate Controller · Tessera Therapeutics
Stephen Garbacz was SVP Finance and Corporate Controller at Tessera Therapeutics (2021–2026), VP Finance and Corporate Controller at Anika (2019–2021), SVP Finance and Operations at Spero Therapeutics (2015–2019) and Executive Director Finance - Epizyme at Ipsen (2012–2015). Stephen cites three IPOs executed, $1B+ M&A strategy and SEC reporting, so IPO readiness questions fit.
Is this you? Claim your profile and get paid for calls.
Yewande Fashakin
LinkedInExperience: Senior Director of Accounting and Finance Business Processes · BlueRock Therapeutics
With 20+ years of life science accounting, Yewande Fashakin has been Senior Director of Accounting and Finance Business Processes at BlueRock Therapeutics since 2025 while holding Director Of Accounting there since 2020. Yewande was Associate Director, Accounting (2018–2020) and Senior Manager, Accounting (2016–2018) at CRISPR Therapeutics and Manager of Accounting at FORUM Pharmaceuticals (2010–2016), and cites budget and forecast analysis.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For R&D budgeting under shifting program timelines, Jaimy Mauricio, Azfar Qureshi and Jamie Caswell hold or held FP&A titles, and Azfar describes being the first finance hire at three companies. Close, controls and SEC reporting questions suit Stephen Garbacz, Estee Silk, Robert Hill, Geraldine Hegarty and Yewande Fashakin, while Parker Munson covers manufacturing site finance and Julie Jones regional finance in emerging markets.
Questions to take into the conversation
- 01How do you build a budget when a program's next milestone could slip by two quarters?
- 02How do you split shared research and manufacturing costs across programs so funding decisions stay fair?
- 03What does a biotech finance team need in place a year before an IPO?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.